New Insulins for Type 1 Diabetes treatment

Simple item page
dc.contributor.authorCarmi, Hana Karime Rumie
dc.contributor.authorDominguez-Menendez, Gonzalo
dc.contributor.authorAraya, Manuel
dc.contributor.authorMartinez-Aguayo, Alejandro
dc.date.accessioned2025-01-20T20:09:04Z
dc.date.available2025-01-20T20:09:04Z
dc.date.issued2023
dc.description.abstractInsulin therapy is complex in pediatric patients because they present greater variations in insulin requirements. Traditional insulins have limitations related to time of onset of action and duration of effect, which has led to the development of new insulins, seeking to reduce chronic complications, severe or nocturnal hypoglycemia, and to improve adherence to therapy. This review updates the information on new insulins, their mechanisms of action and the benefiits they provide in the treatment of diabetes. Insulin analogues attempt to mimic the physiological secretion of the hormone, including time of action and duration of effect. The most used prandial analogs are the so-called rapid-acting insulins, including Faster Aspartic and the new basal insulins, glargine U300 and degludec, which have a prolonged action of more than 24 hours and therefore require a daily dose. New technologies under development include biosimilar insulins such as the glargine biosimilar, already available in the clinic. New formulations are being developed for the future, as well as novel ways of dispersing them, mimicking the action of pancreatic cells, which will allow a more physiological and personalized management of the disease.
dc.fuente.origenWOS
dc.identifier.doi10.32641/andespediatr.v94i3.4477
dc.identifier.eissn2452-6053
dc.identifier.urihttps://doi.org/10.32641/andespediatr.v94i3.4477
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91965
dc.identifier.wosidWOS:001026896900002
dc.issue.numero3
dc.language.isoen
dc.pagina.final285
dc.pagina.inicio278
dc.revistaAndes pediatrica
dc.rightsacceso restringido
dc.subjectType 1 Diabetes Mellitus
dc.subjectInsulin
dc.subjectHypoglycemia
dc.subjectLong-Acting Insulin
dc.subjectShort-Acting Insulin
dc.subjectBiosimilar Pharmaceuticals
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleNew Insulins for Type 1 Diabetes treatment
dc.typeartículo
dc.volumen94
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas